Navigation Links
Hollis-Eden Pharmaceuticals Announces Appointment of Dr. James M. Frincke President and CEO
Date:6/15/2009

SAN DIEGO, June 15 /PRNewswire-FirstCall/ -- Hollis-Eden Pharmaceuticals, Inc. (Nasdaq: HEPH), a leader in the development of a new class of small molecule compounds based on endogenous adrenal steroid hormones, today announced the board of directors has appointed James M. Frincke Ph.D. as President and CEO of Hollis-Eden Pharmaceuticals, Inc. Dr. Frincke was also elected to the company's board of directors.

Dr. Frincke joined Hollis-Eden as Vice President, Research and Development in 1997, was promoted to Executive Vice President in 1999, and to Chief Scientific Officer in 2001. Dr. Frincke joined Hollis-Eden from Prolinx, Inc., where he served as Vice President, Therapeutics Research and Development from 1995 to 1997. During his 28 years in the biotechnology industry, Dr. Frincke has managed major development programs including drugs, biologicals, and cellular and gene therapy products aimed at the treatment of cancer, infectious diseases and organ transplantation. Since joining the biotechnology industry, Dr. Frincke has held vice president, research and development positions in top tier biotechnology companies including Hybritech/Eli Lilly and SyStemix Inc. (acquired by Novartis). In various capacities, he has been responsible for all aspects of pharmaceutical development including early stage research programs, product evaluation, pharmacology, manufacturing, and the management of regulatory and clinical matters for lead product opportunities. Dr. Frincke has authored or co-authored more than 100 scientific articles, abstracts and regulatory filings. Dr. Frincke received his B.S. in Chemistry and his Ph.D. in Chemistry from the University of California, Davis. Dr. Frincke completed his postdoctoral work at the University of California, San Diego. Dr. Frincke has been with Hollis-Eden for more than 11 years.


'/>"/>
SOURCE Hollis-Eden Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Cumberland Pharmaceuticals Announces FDA Approval of Caldolor(TM)
2. Neurim Pharmaceuticals Reports Long Term Efficacy and Safety for Circadin(R) for Insomnia in Elderly Patients
3. Jubilant to Work With Endo Pharmaceuticals on Drug Development
4. Access Pharmaceuticals Announces Granting of Two US Patents for MuGard(TM)
5. ADVENTRX Pharmaceuticals Announces Financing
6. Keryx Biopharmaceuticals Reports Positive Phase 2 Study Results of Zerenex (Ferric Citrate) for the Treatment of Hyperphosphatemia in End-Stage Renal Disease Patients
7. Angiotech Pharmaceuticals announces FDA 510(k) clearance of the Option(TM) Inferior Vena Cava Filter
8. Celator(R) Pharmaceuticals Presents Data on the Activity of CPX-351 Against Leukemia at the European Hematology Association Congress
9. Poniard Pharmaceuticals to Present at the 8th Annual Needham Life Sciences Conference
10. Arena Pharmaceuticals to Present at the 8th Annual Needham Life Sciences Conference
11. Anadys Pharmaceuticals, Inc. Announces Strategic Restructuring to Focus Operations on Continuing the Advancement of ANA598
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/26/2015)... On behalf of biotech client GenScript ... Goldman & Spitzer, P.A. (Wilentz) secured a significant jury ... in excess of $10 million. The jury determined that ... that it improperly hired one or more of GenScript,s ... judgment notwithstanding the verdict, a new trial, and remittitur. ...
(Date:2/26/2015)... Feb. 26, 2015 Protiviti ( www.protiviti.com ), ... of the Governance Portal , designed to increase ... compliance (GRC) tasks across multiple business units and projects. ... help customers better align their controls with the COSO ... ) requirements. In response to client feedback, Protiviti has ...
(Date:2/26/2015)... , Feb. 26, 2015 The healthcare landscape is ... arena, Frost & Sullivan will host its 20 th ... MindXchange , March 8 to 10, at the Hilton San ... This event is a platform for ... to discuss industry disruptions and how to succeed in an ...
(Date:2/26/2015)... (PRWEB) February 26, 2015 RURO, Inc., ... released FreezerPro® version 6.2 – the latest update to ... reputation is that of a quick and easy method ... With the latest version, RURO engineering has enhanced the ... to move large amounts of sample records. , ...
Breaking Biology Technology:Wilentz Client GenScript Awarded $10 Million in Trade Secrets Case Against Genewiz 2Wilentz Client GenScript Awarded $10 Million in Trade Secrets Case Against Genewiz 3Protiviti Governance Portal Helps Companies Drive Governance, Risk and Compliance Productivity Across Multiple Business Units 2Protiviti Governance Portal Helps Companies Drive Governance, Risk and Compliance Productivity Across Multiple Business Units 3Embrace the Future of Medical Technologies with Frost & Sullivan 2Embrace the Future of Medical Technologies with Frost & Sullivan 3RURO Releases FreezerPro® version 6.2 2
... Science ... ... -- DuPont was named the 2009 recipient of the Corporate Innovation Award by the ... that has made a substantial difference in the marketplace and global community., , , ...
... experiment by college students that will study how microbes grow ... , (Logo: http://www.newscom.com/cgi-bin/prnh/20081007/38461LOGO ) , ... developed the experiment that will fly as part of the ... p.m. EST on Nov. 16 from NASA,s Kennedy Space Center ...
... 12 Hollis-Eden Pharmaceuticals, Inc. (Nasdaq: HEPH ), ... I/II open-label dose-ranging trial with Apoptone® (HE3235) for hormone-resistant ... on November 16 at the American Association for Cancer ... Boston. Apoptone, a novel steroid that is an ...
Cached Biology Technology:DuPont Receives Corporate Innovation Award 2DuPont Receives Corporate Innovation Award 3DuPont Receives Corporate Innovation Award 4Students Send Microbe Experiment on Space Shuttle Atlantis 2Students Send Microbe Experiment on Space Shuttle Atlantis 3Hollis-Eden to Present Interim Data From Its Phase I/II Clinical Studies of Apoptone(R) (HE3235) at Molecular Targets and Cancer Therapeutics Conference 2Hollis-Eden to Present Interim Data From Its Phase I/II Clinical Studies of Apoptone(R) (HE3235) at Molecular Targets and Cancer Therapeutics Conference 3Hollis-Eden to Present Interim Data From Its Phase I/II Clinical Studies of Apoptone(R) (HE3235) at Molecular Targets and Cancer Therapeutics Conference 4Hollis-Eden to Present Interim Data From Its Phase I/II Clinical Studies of Apoptone(R) (HE3235) at Molecular Targets and Cancer Therapeutics Conference 5
(Date:2/11/2015)... , February 11, 2015 ... report "Access Control Market by Product (Cards and Readers, ... Military and Defense, Government, Industrial, Healthcare, Education) and By ... by MarketsandMarkets, the Access Control Market is ... growing at a CAGR of 10.6% between ...
(Date:2/9/2015)... , Feb. 9, 2015  Lintec of America recently ... for carbon nanotube (CNT) macrostructures, including sheets, yarns and ... (UTD). Leveraging the vast industrial resources of ... Japan , Lintec of America is forming the ... TX , focusing on scaling up the manufacturing ...
(Date:2/5/2015)... , Feb. 5, 2015  Marken is starting ... company and has launched a new marketing campaign to ... Organization (CLO).  The new campaign focuses on First ... protocol and shipments. The first headline in ... aligns Marken,s priorities with its client,s priorities. Marken recognizes ...
Breaking Biology News(10 mins):Access Control Market Worth $10.4 Billion by 2020 2Access Control Market Worth $10.4 Billion by 2020 3Access Control Market Worth $10.4 Billion by 2020 4Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 2Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 3Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 4Marken Launches New Patient-Centric Campaign 2
... immune system's pro-inflammatory response to bacterial invasion is ... called inducible nitric oxide synthase. In a study ... report that the predominantly anti-inflammatory enzyme, endothelial nitric ... production in response to infection. This discovery may ...
... Until now it has been impossible to accurately measure ... in real time and at the level of a ... Plant Biology and Stanford University are the first to ... molecular sensors to view changes in brain chemical levels. ...
... (MGH) has identified 80 new genes essential to the ... tool for inactivating genes in plants or animals. They ... that participate in the gene-silencing mechanism, which someday may ... in the journal Science and is receiving early online ...
Cached Biology News:Researchers report new pro-inflammatory role for anti-inflammatory enzyme 2Revolutionary nanotechnology illuminates brain cells at work 2Revolutionary nanotechnology illuminates brain cells at work 3Scientists identify genetic pathways essential to RNA interference 2Scientists identify genetic pathways essential to RNA interference 3
... PROTEAN II xi multi-cell is for 2-D separations. ... cooling capabilities. The PROTEAN II xi multi-cell can ... type of glass plates, and cooling system. The ... to the PROTEAN II XL multi-cell for a ...
F40 piston seals are supplied as 2 seals with a seal tool to service one F40 pump of a BioLogic DuoFlow workstation....
... probe for DNA. Binds to the minor ... rich DNA), forming a stable complex which ... alone. DAPI is several times more sensitive ... agarose gels. It may be used for ...
Mol wt: monoisotopic mol wt1,045.5423 Da by calculation...
Biology Products: